In vitro cytostatic activity of 1,2,4-triazolo- and 1,2,3,4-tetrazolo pyridazines

Polish Journal of Pharmacology

Volumn 49, Issue 6, 1997, Pages 471-477

  Hładoń, Bogusław ^a   Laskowska, Halina ^a   Sloderbach, Anna ^a   Melzer, Ewa ^a,b  

^a Department of Pharmacology ^*  (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cytostatic activity; Tetrazolopyridazines; Triazolopyridazines

Indexed keywords

1,2,3,4 TETRAZOLO[1,5 B]PYRIDAZINE DERIVATIVE; 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE DERIVATIVE; CYTARABINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CYTOSTASIS; DRUG SCREENING; DRUG SOLUBILITY; HELA CELL; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; KB CELLS; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; TRIAZOLES;

EID: 2642701736     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bałoniak S., Chylak J., Mroczkiewicz A.: Antimicrobial activity of halogenic derivatives of pyridazine. Ann. Med. Acad., Poznań, 1974, VIII, 131-135.
2. Bałoniak S., Katrusiak A.: Synthesis and reactivity of some 1,2,4-triazolo(4,3-b)pyridazine derivatives. Pol. J. Chem., 1994, 68, 683-691.
3. Biagi G., Ferreti M., Giorgi I., Livi O., Scartoni V., Lucacchini A.: 1,2,3-Triazole(4,5-d)pyridazines-I analogues of prostaglandin synthesis inhibitors. Farmaco, 1993, 48, 1159-1165.
4. Biagi G., Giorgi I., Livi O., Scartoni V., Velo S., Martini C., Senatore G., Barili P. L.: 1,2,3-Triazole-(4,5-d)pyridazines. IV Preparation and adenosine receptor binding of new 4 and/or 7 aminoderivatives. Farmaco, 1995, 50, 99-105.
5. Bussolari J. C., Ramesh K., Stockler J. D., Chen S. F., Panzica R. P.: Synthesis and biological evaluation of N 4-substituted imidazo- and v-triazolo(4,5-d)pyridazine nucleosides. J. Med. Chem., 1993, 36, 4113-4120.
6. Ciszewski K., Celewicz L., Golankiewicz K.: Synthesis of 6-substituted tetrazolo(1,5-c)pyrimidin-5(6H)-ones: new modification of 3′-azido-3′-deoxythymidine. Biochem. Biophys. Res. Commun., 1992, 187, 1545-1550.
7. Długosz A.: Synthesis and biological activity of pyrimidobenzodiazepine derivatives. New ring systems: triazolo- and tetrazolo-pyrimido-benzodiazepines. Pharmazie, 1995, 50, 180-182.
8. Eagle H., Foley G. H.: The cytotoxic action of carcinolytic agents in tissue culture. Amer. J. Med., 1956, 21, 739-749.
9. Elion E.: The pharmacology of azathioprine. Ann. N Y Acad. Sci., 1993, 685, 401-410.
10. Geran R. J., Greenberg N. M., Mc Donald M. M., Schumacher A. M., Abbott B. J.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 1972, 3, 59-61.
11. Hanks J. H., Fawcett D. W., Scherer W. F., Leighton J., Porter K R.: Introduction to Cell and Tissue Culture, Burges Publ. Co., Minneapolis, 1955, 17-21.
12. Heinisch G., Frank H.: Pharmacologically active pyridazine derivatives. Part 1. In: Progress in Medicinal Chemistry. Eds. Ellis G. P., West G. B.. Elsevier Science Publ., B. V., Amsterdam, 1990, 27, 1-49.
13. Hładoń B., Bałoniak S., Szafarek P., Zyczyńska-Bałoniak I.: Cytostatic activity of pyridazine derivatives. I. In vitro studies on 1-methoxyphenylpyridazine-6-ones. Arch. Immunol. Ther., Exp., 1980, 28, 427-432.
14. Hładoń B., Gutsche W., Bałoniak S., Sikorska H.: Experimental antitumor activity of new azathioprine analogues. Arzneim.-Forsch.-Drug Res., 1989, 39, 78-81.
15. Hładoń B., Palka Z.: Computer evaluation of cytostatic properties of compounds. I. In vitro studies on inhibitory and stimulative activities by CY-VTP/1 program for ODRA-1204 computer. Arch. Immunol. Ther. Exp., 1980, 28, 409-418.
16. Hładoń B., Palka Z.: Computer evaluation of cytostatic properties of compounds. II. In vitro studies on the ac tivities by CY-VTP/2 program for ODRA-1204 computer. Arch. Immunol. Ther. Exp., 1980, 28, 419-426.
17. Hładoń B., Sloderbach A., Radosh P., Spychała J., Golankiewicz K.: In vitro cytostatic activity of some amino acid 4-N-substituted cytosines. Arch. Immunol. Ther. Exp., 1992, 40, 145-150.
18. Hładoń B., Szafarek P., Bałoniak S., Mroczkiewicz A.: Cytostatic activity of pyridazine derivatives. Part II. In vitro studies on halogen derivatives of 6-pyridazinone and 3,6-pyridazinedione. Pol. J. Pharmacol. Pharm., 1981, 33, 445-452.
19. Katrusiak A. A., Bałoniak S., Katrusiak A. S.: Reactivity of triazolo- and tetrazolopyridazines. Pol. J. Chem., 1996, 70, 1279-1289.
20. Lagorce J. F., Moulard T., Raby C.: Synthesis and inhibitory effects of 1,2,4-triazole derivatives on platelet aggregation. Arzneim.-Forsch.-Drug Res., 1992, 42, 314-318.
21. National Cancer Institute, Division of Cancer Treatment, Drug Research and Development. Program Procedure. Instruction and technical documentation change notice, instruction 14. Screening data summary interpretation and outline of current screening. Edition NCI, NIH, Bethesda, Rev., 1980, 6, 31-62.
22. Oyama V. J., Eagle H.: Measurment of cell growth in tissue culture with a phenol reagent (Folin-Ciocalteau). Proc. Soc. Exp. Biol. Med., 1956, 91, 305-307.
23. Pearson E. S., Hertley H. G.: Biometrie Tables for Statisticians, Cambridge Press, London, 1962, 165.
24. Rubat C., Coudert P., Couqulet J. M., Tronche P., Bastide J., Bastide P.: Synthesis and pharmacological evaluation of 6,8-diaryl-1,2,4-triazolo(4,3-b) and 1,2,3,4-tetrazolo(1,5-b)pyridazines. Farmaco, 1990, 45, 331-340.
25. Smith C. G., Lumnis W. L., Grady J. E.: An improved tissue culture assay I. Methodology and cytotoxicity of antitumor agent. Cancer Res., 1959, 19, 843-846.
26. Weber E.: Grundriss der Biologischen Statistik, VEB G. Fischer Verlag, Jena, 1957, 45-46.